Sign in
Taking peopleNo phase

Vitamin D for Acute Intracerebral Hemorrhage

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
40 people, planned
Started
1 Mar 2026
Expected to end
28 Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vitamin D
Record updated
6 May 2026

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Spontaneous ICH diagnosis
  • Age ≥ 18 years
  • Within 96 hours of ICH
  • Premorbid Modified Rankin Scale of ≤2
  • Supratentorial ICH
  • ICH volume ≥2 mL

Who cannot take part

  • Anticipated surgical evacuation of hematoma
  • History of kidney stones
  • Bleeding tendency
  • Severe renal impairment
  • Severe liver impairment
  • Known contraindication or allergy to vitamin D
  • Expected life expectancy of <1 year
  • Glasgow Coma Scale <9
  • Inability to participate in follow-up activity
  • Hypercalcemia
  • Hyperphosphatemia

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Intracerebral hemorrhage (ICH) is the most deadly and debilitating form of stroke. To date, effective treatment that could improve the functional outcome of ICH remained elusive. In a mice model of ICH, it was demonstrated that high dose Vitamin D (VitD) treatment enhanced hematoma resolution by promoting reparative macrophage differentiation and improved neurobehavioral performance in mice. Hence, this pilot study aimed to investigate the feasibility and safety of VitD treatment for ICH in human subjects.

Read full original descriptionShow less

VICToHR is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. Participants will be randomized 1:1 to receive either VitD or standard care (control). The intervention group will receive VitD 4000 IU daily for 2 weeks, followed by 1000 IU daily for 24 weeks. The primary outcomes are the rate of hematoma resolution at 14 days and the incidence of hypercalcemia and VitD toxicity. Hematoma volume will be assessed by a neuroradiologist who is blinded to treatment allocation.

The 2 groups in the trial

  • Vitamin D armExisting treatment, for comparison

    Vitamin D 4000 IU daily for 2 weeks followed by 1000 IU for 24 weeks

    Treatment: Vitamin D

  • Control armNo study treatment, for comparison

    No vitamin D

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Vitamin D Treatment in IntraCerebal Hemorrhage To Enhance Hematoma Resolution (VICToHR): a Pilot Study
Criteria questions
Built from NCT07458815, who can take part
Record updated
6 May 2026